Similar articles

• Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.

  Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M, Portales RG, González-Mari MV, Laffón A, García-Vicuña R. Fernández-Nebro A, et al. Am J Med. 2005 May;118(5):552-6. doi: 10.1016/j.amjmed.2005.01.028. Am J Med. 2005. PMID: 15866260 Clinical Trial. No abstract available.
• [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].

  Manger B; Kommission Pharmkotherapie, Deutsche Gesellschaft für Rheumatologie. Manger B, et al. Z Rheumatol. 2002 Dec;61(6):694-7. doi: 10.1007/s00393-002-0451-1. Z Rheumatol. 2002. PMID: 12491133 Review. German. No abstract available.
• [TNF-alpha inhibitors].

  Fain O. Fain O. Rev Prat. 2003 Nov 30;53(18):1989-90. Rev Prat. 2003. PMID: 15008210 French. No abstract available.
• Etanercept (Enbrel) -- an update.

  Goffe B. Goffe B. Skin Therapy Lett. 2004 Dec-2005 Jan;9(10):1-4, 9. Skin Therapy Lett. 2004. PMID: 15657632 Review.
• New-onset psoriasis associated with etanercept therapy.

  Chen LA, Su LH, Chang YJ, Hsu YL, Tsai TH. Chen LA, et al. J Dermatol. 2010 Apr;37(4):378-80. doi: 10.1111/j.1346-8138.2010.00789.x. J Dermatol. 2010. PMID: 20507411 Review. No abstract available.